NEW YORK--(BUSINESS WIRE)--Feb. 20, 2019--
Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading
U.S.-based multi-platform gene therapy company, today announces that
Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will
participate in a fireside chat at the 8th Annual SVB Leerink Global
Healthcare Conference in New York City. The fireside chat will take
place on Wednesday, February 27, 2019, at 11:00 a.m. Eastern Time.
A live audio webcast of the fireside chat will be available on the
Investors section of the company’s website, www.rocketpharma.com.
A replay of the presentation will be archived on the Rocket website
following the conference.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (“Rocket”) is an emerging,
clinical-stage biotechnology company focused on developing
first-in-class gene therapy treatment options for rare, devastating
diseases. Rocket’s multi-platform development approach applies the
well-established lentiviral vector (LVV) and adeno-associated viral
vector (AAV) gene therapy platforms. Rocket's lead clinical program is a
LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a
difficult to treat genetic disease that leads to bone marrow failure and
potentially cancer. Preclinical studies of additional bone
marrow-derived disorders are ongoing and target Pyruvate Kinase
Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile
Malignant Osteopetrosis (IMO). Rocket’s first AAV-based gene therapy
program targets Danon disease, a rare neuromuscular and cardiovascular
disease. For more information about Rocket, please visit www.rocketpharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190220005015/en/
Source: Rocket Pharmaceuticals, Inc.
Claudine Prowse, Ph.D.
SVP, Strategy, Corporate Development and IRO
The Empire State Building, Suite 7530